News

OmniComm Systems has announced that a major West coast biopharmaceutical company has selected OmniComm to provide eClinical solutions for two of its phase I HIV studies. Both HIV

Simulations Plus has received a purchase order from FDA to expand the number of licenses for the company’s GastroPlus simulation software. Ron Creeley, vice president of marketing and

MSD India, a subsidiary of Merck and Co., is planing to expand its presence in the Indian market – reported Hindustan Times. The company is currently ascertaining possible

Molecular Insight has initiated a pivotal phase 2 clinical trial of Azedra for the treatment of malignant pheochromocytoma, a type of neuroendocrine cancer. The single-arm trial will evaluate

ALDA Pharmaceuticals (ALDA) has reported that in tests conducted at an independent laboratory in the US, T36 Antiseptic Hand Sanitizer has been shown to completely kill the new

For the quarter ended June 30, 2009, Catalyst reported a net loss of $1.76m, or $0.13 per basic and diluted share, compared to a net loss of $2.37m,

Opexa Therapeutics has entered into an agreement with Novartis for the further development of its novel stem cell technology. The technology, which has generated preliminary data showing the

MediGene, in co-operation with the British drug regulatory authority – Medicines and Healthcare Products Regulatory Agency, has conducted a series of in-vitro studies to rule out any potential

FDA has approved Bayer HealthCare Pharmaceuticals’ 3000 IU vial size of Kogenate FS, antihemophilic factor (recombinant). The company said that the 3000 IU vial may eliminate the need